Pfizer Inc. awarded $4.15B for COVID-19 vaccines, highlighting a sole-source procurement for biological products

Contract Overview

Contract Amount: $4,150,835,100 ($4.2B)

Contractor: Pfizer Inc

Awarding Agency: Agency for International Development

Start Date: 2021-07-30

End Date: 2024-02-29

Contract Duration: 944 days

Daily Burn Rate: $4.4M/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: COVID-19 VACCINES FOR INTERNATIONAL DONATION

Place of Performance

Location: NEW YORK, NEW YORK County, NEW YORK, 10017

State: New York Government Spending

Plain-Language Summary

Agency for International Development obligated $4.15 billion to PFIZER INC for work described as: COVID-19 VACCINES FOR INTERNATIONAL DONATION Key points: 1. Significant investment in global health security through vaccine provision. 2. Sole-source procurement raises questions about price discovery and potential cost savings. 3. Contract duration of over two years suggests a sustained need for vaccine supply. 4. Focus on a single supplier may limit market competition and innovation. 5. Geographic focus on international donation indicates a humanitarian aid objective. 6. The contract's value represents a substantial portion of federal spending in this category.

Value Assessment

Rating: questionable

The contract value of $4.15 billion for COVID-19 vaccines is substantial. Without comparable sole-source contracts for similar quantities and delivery timelines, a precise value-for-money assessment is difficult. However, the absence of competition inherently limits the government's ability to benchmark pricing against market alternatives or secure potentially lower prices through a competitive bidding process. This raises concerns about whether the government achieved the best possible price.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning it was not competed. This approach is typically used when only one responsible source is available or when a compelling justification exists for not seeking competition. The lack of multiple bidders means there was no direct price negotiation or comparison against other suppliers, potentially leading to a higher cost than if the contract had been competed.

Taxpayer Impact: Taxpayers may have paid a premium due to the lack of competitive bidding. Without competition, there is less pressure on the contractor to offer the lowest possible price, potentially resulting in less efficient use of public funds.

Public Impact

International populations will benefit from access to COVID-19 vaccines, aiding global pandemic control. The contract facilitates the delivery of essential biological products to support global health initiatives. The geographic impact is global, focusing on countries receiving international donations. Workforce implications are primarily within Pfizer's manufacturing and distribution networks, with indirect benefits to global health workers.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source procurement limits price competition and potentially increases costs for taxpayers.
Lack of transparency in the sole-source justification could obscure potential alternatives.
High contract value necessitates robust oversight to ensure effective delivery and accountability.
Dependence on a single supplier for a critical health product poses supply chain risks.

Positive Signals

Addresses a critical global health need by providing essential vaccines.
Supports international efforts to combat the COVID-19 pandemic.
Ensures a significant supply of vaccines through a single, established manufacturer.

Sector Analysis

This contract falls within the Pharmaceutical and Medical Preparations Manufacturing sector, specifically for biological products. The global market for vaccines is substantial, driven by ongoing public health needs and pandemic preparedness. This contract represents a significant federal investment in procuring a key product within this sector, likely aimed at fulfilling international aid commitments rather than domestic supply.

Small Business Impact

This contract does not appear to involve small business set-asides. As a sole-source award to a large pharmaceutical company, there are no direct subcontracting opportunities mandated for small businesses within this specific contract. The focus is on the primary manufacturer's capacity to produce and deliver the vaccine.

Oversight & Accountability

Oversight for this contract would typically involve the contracting agency (USAID) and potentially the Office of the Inspector General (OIG) to ensure compliance with contract terms, delivery schedules, and financial accountability. Transparency regarding the justification for the sole-source award and the terms of the agreement is crucial for public accountability.

Related Government Programs

COVID-19 Vaccine Procurement
Global Health Security Initiatives
International Development Assistance
Biological Product Manufacturing

Risk Flags

Sole-source procurement
Lack of competition
High contract value
Potential for price inflation

Frequently Asked Questions

What is this federal contract paying for?

Agency for International Development awarded $4.15 billion to PFIZER INC. COVID-19 VACCINES FOR INTERNATIONAL DONATION

Who is the contractor on this award?

The obligated recipient is PFIZER INC.

Which agency awarded this contract?

Awarding agency: Agency for International Development (Agency for International Development).

What is the total obligated amount?

The obligated amount is $4.15 billion.

What is the period of performance?

Start: 2021-07-30. End: 2024-02-29.

What was the specific justification for awarding this contract on a sole-source basis?

The provided data does not detail the specific justification for the sole-source award. Typically, sole-source contracts are justified under circumstances such as the availability of only one responsible source, or when a public exigency requires immediate action and only one source can meet the requirement. For a high-value pharmaceutical contract like this, potential justifications could include unique manufacturing capabilities, proprietary technology, or urgent global health needs that necessitate rapid procurement from a known, capable supplier like Pfizer. Further investigation into the contract's justification documentation would be required for a definitive answer.

How does the per-unit cost of these vaccines compare to other federal procurements or market rates?

The provided data does not include per-unit cost information, making a direct comparison impossible. Furthermore, as this was a sole-source contract, it was not subject to competitive bidding, which typically drives down per-unit costs. Without knowing the exact quantity of vaccines procured under this $4.15 billion contract, calculating a precise per-unit cost is not feasible. Comparisons would ideally be made against other large-scale, government-procured vaccine lots, but the sole-source nature of this award makes benchmarking against market rates or other competitive contracts challenging.

What are the key performance indicators (KPIs) and delivery milestones associated with this contract?

The provided data does not specify the key performance indicators (KPIs) or delivery milestones for this contract. However, for a contract of this magnitude and nature, KPIs would likely include adherence to delivery schedules, vaccine efficacy and safety standards, proper storage and handling during transit, and potentially reporting on distribution to recipient countries. Delivery milestones would be crucial, outlining the phased delivery of vaccine doses over the contract period (July 30, 2021, to February 29, 2024). USAID would be responsible for monitoring these aspects to ensure the successful fulfillment of the contract's objectives.

What is the track record of Pfizer Inc. in fulfilling large-scale government contracts, particularly for vaccines?

Pfizer Inc. has a significant track record in fulfilling large-scale government contracts, particularly in the pharmaceutical sector. Notably, they were a primary supplier of COVID-19 vaccines to numerous governments worldwide, including the U.S. government, through competitive and non-competitive awards. Their ability to rapidly scale up manufacturing and distribution for the COVID-19 vaccine demonstrated considerable capacity. While this specific contract was sole-source, Pfizer's broader experience in producing and delivering billions of vaccine doses globally suggests a strong capability in managing complex, high-volume pharmaceutical procurements.

What is the total federal spending on COVID-19 vaccines for international donation over the past five years?

The provided data only pertains to a single contract valued at $4.15 billion for COVID-19 vaccines for international donation awarded to Pfizer Inc. It does not offer a comprehensive overview of all federal spending in this category. To determine the total federal spending on COVID-19 vaccines for international donation over the past five years, a broader analysis of federal procurement databases (like FPDS or USASpending.gov) would be necessary, filtering for relevant keywords, agencies (e.g., USAID, HHS), and contract types related to vaccine donations. This single contract represents a significant portion of such spending, but a complete picture requires a wider data sweep.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: W58P0521R0005

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 235 E 42ND ST, NEW YORK, NY, 10017

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $6,859,517,906

Exercised Options: $4,150,835,100

Current Obligation: $4,150,835,100

Actual Outlays: $2,826,900

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline